Want to see JP:7600 full AI Analyst Report?
7600 Stock Chart & Stats
¥487.00
-¥2.00(-0.33%)
At close: 4:00 PM EST
¥487.00
-¥2.00(-0.33%)
Day’s Range― - ―
52-Week Range¥445.00 - ¥1,005.00
Previous CloseN/A
Volume41.50K
Average Volume (3M)177.86K
Market Cap
¥15.46B
Enterprise Value¥27.28B
Total Cash (Recent Filing)¥2.56B
Total Debt (Recent Filing)¥6.63B
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.9%
Share Statistics
EPS (TTM)-8.37
Shares Outstanding26,475,880
10 Day Avg. Volume252,960
30 Day Avg. Volume177,856
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)0.56
Price to Sales (P/S)0.59
P/FCF Ratio-8.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.3
Revenue Forecast (FY)¥25.30B
Bulls Say, Bears Say
Bulls Say
Balance Sheet ResilienceModerate leverage and a large equity base provide financial flexibility as the company navigates weaker operations. Although debt has risen from 2024, the current debt-to-equity level remains reasonable, supporting resilience and the capacity to fund business needs without excessive balance-sheet strain.
Return To ProfitabilityReturning to positive earnings demonstrates that the business still has an operating path to profitability despite recent pressure. The narrow margin is a weakness, but renewed profitability can provide a base for recovery if revenue stabilizes and operating efficiency improves over coming quarters.
Demonstrated Prior Cash GenerationThe history of healthy positive free cash flow indicates that the company has previously converted operations into internally generated funds. This supports the possibility of cash-flow recovery if current investment needs or working-capital pressure normalize, preserving a credible longer-term self-funding model.
Bears Say
Revenue ContractionThe shift from strong revenue growth in 2022–2024 to a year-over-year decline signals weakening demand or execution momentum in the core business. Sustained contraction would reduce operating leverage, limit reinvestment capacity, and make a durable earnings recovery more difficult.
Severe Margin CompressionSharp compression in operating and net margins leaves little room for further cost or revenue pressure before profitability is impaired. It also indicates that prior revenue growth translated less effectively into earnings, weakening the company’s ability to compound returns unless margins recover.
Deteriorating Cash GenerationDeeply negative free cash flow and sharply lower operating cash flow weaken earnings quality and increase reliance on available funding. With operating cash flow only about 0.03 times net income, the company has less internally generated cash to support investment, liquidity, or shareholder returns.
Japan Medical Dynamic Marketing, Inc. News
7600 FAQ
What was Japan Medical Dynamic Marketing, Inc.’s price range in the past 12 months?
Japan Medical Dynamic Marketing, Inc. lowest stock price was ¥445.00 and its highest was ¥1005.00 in the past 12 months.
What is Japan Medical Dynamic Marketing, Inc.’s market cap?
Japan Medical Dynamic Marketing, Inc.’s market cap is ¥15.46B.
When is Japan Medical Dynamic Marketing, Inc.’s upcoming earnings report date?
Japan Medical Dynamic Marketing, Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 6 days.
How were Japan Medical Dynamic Marketing, Inc.’s earnings last quarter?
Japan Medical Dynamic Marketing, Inc. released its earnings results on Jul 30, 2026. The company reported -¥15.85 earnings per share for the quarter.
Is Japan Medical Dynamic Marketing, Inc. overvalued?
According to Wall Street analysts Japan Medical Dynamic Marketing, Inc.’s price is currently Overvalued.
Does Japan Medical Dynamic Marketing, Inc. pay dividends?
Japan Medical Dynamic Marketing, Inc. pays a Annually dividend of ¥17 which represents an annual dividend yield of 2.9%. See more information on Japan Medical Dynamic Marketing, Inc. dividends here
What is Japan Medical Dynamic Marketing, Inc.’s EPS estimate?
Japan Medical Dynamic Marketing, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Medical Dynamic Marketing, Inc. have?
Japan Medical Dynamic Marketing, Inc. has 26,475,880 shares outstanding.
What happened to Japan Medical Dynamic Marketing, Inc.’s price movement after its last earnings report?
Japan Medical Dynamic Marketing, Inc. reported an EPS of -¥15.85 in its last earnings report. Following the earnings report the stock price went down -3.444%.
Which hedge fund is a major shareholder of Japan Medical Dynamic Marketing, Inc.?
Currently, no hedge funds are holding shares in JP:7600
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Medical Dynamic Marketing, Inc.
Japan Medical Dynamic Marketing, Inc. (JMDM) engages in the development, production, importation, and distribution of medical instruments throughout Japan and the United States. Its product portfolio features a variety of trauma devices, including surgical nails, screws, and plates, engineered for implantation at fracture sites. JMDM also offers joint prostheses, which are designed to replace compromised natural joints and restore functions impaired by disease or injury. Additionally, the company supplies spinal stabilization systems for operations addressing spinal instability, as well as synthetic bone grafts used in the treatment of bone fractures, tumors, and other structural deficiencies. These specialized medical solutions are provided to healthcare professionals and hospitals. Founded in 1973, the firm's headquarters are located in Tokyo, Japan.
Technical Analysis
CYBERDYNE
―
PHC Holdings Corp.
―
Eiken Chemical Co., Ltd.
―
Techno Medica Co., Ltd.
―
Nihon Kohden Corporation
―